What they were paid
Kyverna Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | $0 | $0 | $0 | $0 |
| FY2024 | $0 | — | $0 | $0 | $0 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kyverna Therapeutics, Inc. DEF 14A filed April 13, 2026, accession 0001193125-26-152835, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Kyverna Therapeutics pays directors a $40,000 cash retainer.
The rest of the Kyverna Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Andrew Miller, Ph.D | Independent Director | — |
| Beth Seidenberg, M.D | Independent Director | $242,452 |
| Christi Shaw | Chair of the Board | $319,892 |
| Daniel K. Spiegelman | Independent Director | $234,952 |
| Fred E. Cohen, M.D., D.Phil | Independent Director | $237,452 |
| Ian Clark | Independent Director | $259,952 |
| Mert Aktar | Independent Director | $232,452 |
| Sravan Emany | Independent Director | — |
| Warner Biddle | Director | $0 |
The full Kyverna Therapeutics compensation record
free company briefThis page is one director within Kyverna Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat